Cargando…
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
SIMPLE SUMMARY: Advanced urothelial bladder cancer (BC) shows a heterogeneous response to both platinum and immune checkpoint inhibitor (ICI) therapies. The PD-1/PD-L1 signaling pathway represents an immune escape mechanism and tissue PD-L1 expression was shown to be associated with patients’ progno...
Autores principales: | Krafft, Ulrich, Olah, Csilla, Reis, Henning, Kesch, Claudia, Darr, Christopher, Grünwald, Viktor, Tschirdewahn, Stephan, Hadaschik, Boris, Horvath, Orsolya, Kenessey, Istvan, Nyirady, Peter, Varadi, Melinda, Modos, Orsolya, Csizmarik, Anita, Szarvas, Tibor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196869/ https://www.ncbi.nlm.nih.gov/pubmed/34067347 http://dx.doi.org/10.3390/cancers13112548 |
Ejemplares similares
-
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
por: Váradi, Melinda, et al.
Publicado: (2023) -
High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
por: Széles, Ádám, et al.
Publicado: (2022) -
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
por: Olah, Csilla, et al.
Publicado: (2020) -
Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
por: Kovács, Petra Terézia, et al.
Publicado: (2022) -
Why are upper tract urothelial carcinoma two different diseases?
por: Szarvas, Tibor, et al.
Publicado: (2016)